Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 9/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810615 | 0.86 | MAPT (0.52) | MAPTALDH1A1MAPK1LMNARAF1 | |
| SCHEMBL811476 | 0.86 | MAPT (0.43) | MAPTALDH1A1MAPK1LMNARAF1 | |
| SCHEMBL7031491 | 0.80 | MAPT (0.55) | MAPTALDH1A1MAPK1LMNARAF1 | |
| SCHEMBL9652296 | 0.77 | MAPT (0.56) | MAPTALDH1A1MAPK1LMNARAF1 | |
| SCHEMBL809916 | 0.76 | MAPT (0.46) | MAPTALDH1A1LMNAMEN1HTT | |
| SCHEMBL29502891 | 0.76 | FFAR1 (0.44) | MAPTALDH1A1MAPK1LMNACYP2D6 | |
| SCHEMBL20526922 | 0.76 | FFAR1 (0.44) | MAPTALDH1A1MAPK1LMNACYP2D6 | |
| SCHEMBL2080670 | 0.74 | VCAM1 (0.51) | MAPTALDH1A1MAPK1LMNARAF1 | |
| SCHEMBL29024322 | 0.74 | MAPK1 (0.40) | MAPTALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL31402301 | 0.74 | MAPK1 (0.40) | MAPTALDH1A1MAPK1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885ALDH1A1 2723/4885MAPK1 2917/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885ALDH1A1 2723/4885MAPK1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.